The annual meeting of ASCO (American Society of Clinical Oncologists) is this weekend, and Crizotinib is attracting some attention. Today the plenary session will include accumulated data from the PF-02341066 trial and already there are several online articles in which Crizotinib is discussed.
Medpage has a video interview with the PI (Principal Investigator) of the trial, Dr. Alice Shaw. She is also my oncologist.
A reporter from Bloomberg Businessweek spoke to me some weeks ago, and today there is an online story about Crizotinib which mentions some of my own experience on trial.
And the Sunday New York Times featured an article in today’s paper that references two promising new cancer therapies; Crizotinib is one of them.
It’s really very exciting to witness and to have been fortunate enough to have participated in what I hope is merely the groundswell of a new era in cancer treatment. That this innovation should also be happening in lung cancer, the cancer that kills more people than all other cancers and which has been notoriously difficult to treat at all but the earliest stages, well, hallelujah.